Clinical trials
Genital Neoplasms, Male trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
21 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Terminated | 7 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Approved for marketing | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Advanced Accelerator Applications | 2 |
| NanOlogy, LLC | 2 |
| Steba Biotech S.A. | 2 |
| Alessandro D'Agnolo | 1 |
| Aragon Pharmaceuticals, Inc. | 1 |
| Astellas Pharma Global Development, Inc. | 1 |
| Cedars-Sinai Medical Center | 1 |
| Dendreon | 1 |
| ESSA Pharmaceuticals | 1 |
| Janssen Research & Development, LLC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Genital Neoplasms, Male | 21 |
| Prostatic Neoplasms | 20 |
| Urogenital Neoplasms | 19 |
| Prostatic Diseases | 14 |
| Genital Diseases, Male | 11 |
| Neoplasms | 11 |
| Neoplasms by Site | 10 |
| Male Urogenital Diseases | 5 |
| Carcinoma | 4 |
| Neoplasms, Glandular and Epithelial | 3 |
Trials
Showing 1 to 21 of 21. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.